Dr. Daneshmand on Emerging Treatments in Bladder Cancer

Sia Daneshmand MD, professor of Urology, Keck School of Medicine, University of Southern California, discusses emerging treatments in bladder cancer.

For patients with low-grade, non-muscle invasive bladder cancer, surveillance is an acceptable approach, and for patients with advanced disease, systemic therapies have a role, Daneshmand says. Though the practice of surveillance is not new, more data have emerged on how to perform it, the safety involved, and the rates of progression for patients with low-grade, non-muscle invasive bladder cancer, Daneshmand adds. Combination therapies have started to find a place in advanced bladder cancer, and ongoing trials continue to investigate these regimens, Daneshmand explains.

Regarding currently available therapies, retrospective studies have shown the benefits of gemcitabine plus docetaxel, and more long-term data have been seen regarding the regimen, Daneshmand concludes.